Physician profile
Kendrick Bashor
NPI 1457355083
$9,078.93
in general payments reported to CMS, 2019-2025
34 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $1,135 · 2021: $1,154 · 2022: $1,102 · 2023: $1,968 · 2024: $1,213 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,495.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,293.08 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $1,013.95 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $1,002.53 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $811.05 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lundbeck LLC | $717.31 | 2019-2025 | Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $704.32 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Novo Nordisk INC | $462.46 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $376.89 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $370.57 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $351.67 | 2020-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $327.48 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Astellas Pharma US INC | $220.74 | 2019-2023 | Veozah |
| Indivior INC. | $190.05 | 2019-2025 | Perseris, Sublocade |
| Amarin Pharma, INC. | $168.41 | 2019 | |
| Allergan, INC. | $161.54 | 2019-2020 |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendrick Bashor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.